Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Farallon Capital Management LLC

Farallon Capital Management LLC trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 23.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 290,000 shares of the company’s stock after selling 87,400 shares during the quarter. Farallon Capital Management LLC owned about 0.27% of Vaxcyte worth $21,898,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Parallel Advisors LLC lifted its stake in shares of Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Vaxcyte in the 2nd quarter valued at approximately $35,000. Fidelis Capital Partners LLC purchased a new stake in shares of Vaxcyte in the first quarter valued at approximately $37,000. J.Safra Asset Management Corp grew its holdings in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after acquiring an additional 526 shares during the period. Finally, Quest Partners LLC purchased a new position in Vaxcyte in the second quarter worth $70,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $112.11 on Tuesday. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of -26.19 and a beta of 0.97. Vaxcyte, Inc. has a one year low of $44.20 and a one year high of $121.06. The company’s 50 day moving average price is $89.68 and its 200 day moving average price is $76.70.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PCVX. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Bank of America upped their price objective on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Jefferies Financial Group upped their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, BTIG Research lifted their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the sale, the senior vice president now directly owns 30,826 shares in the company, valued at $2,354,181.62. The disclosure for this sale can be found here. Insiders sold a total of 78,283 shares of company stock worth $7,064,138 in the last 90 days. 3.10% of the stock is owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.